Johnson & Johnson (JNJ) : First Foundation Advisors scooped up 23,203 additional shares in Johnson & Johnson during the Q4 period, according to a recent disclosure to the SEC. The investment management firm now holds a total of 368,669 shares of Johnson & Johnson which is valued at $39.6 Million.Johnson & Johnson makes up approximately 2.68% of First Foundation Advisors’s portfolio.
Other Hedge Funds, Including , Cypress Capital Group reduced its stake in JNJ by selling 1,425 shares or 1.42% during the fourth quarter. The Hedge Fund company now holds 99,052 shares of JNJ which is valued at $10.6 Million. Johnson & Johnson makes up approx 2.54% of Cypress Capital Group’s portfolio.Barr E S Co reduced its stake in JNJ by selling 6,767 shares or 2.24% during the fourth quarter. The Hedge Fund company now holds 295,323 shares of JNJ which is valued at $31.7 Million. Johnson & Johnson makes up approx 3.80% of Barr E S Co’s portfolio.Guardian Capital Advisors Lp reduced its stake in JNJ by selling 66 shares or 0.07% during the fourth quarter. The Hedge Fund company now holds 91,149 shares of JNJ which is valued at $9.8 Million. Johnson & Johnson makes up approx 1.86% of Guardian Capital Advisors Lp’s portfolio.Massachusetts Financial Services Co reduced its stake in JNJ by selling 455,893 shares or 1.55% during the fourth quarter. The Hedge Fund company now holds 28,983,860 shares of JNJ which is valued at $3,115.8 Million. Johnson & Johnson makes up approx 1.64% of Massachusetts Financial Services Co’s portfolio.
On the company’s financial health, Johnson & Johnson reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jan 26, 2016. Analyst had a consensus of $1.42. The company had revenue of $17811.00 million for the quarter, compared to analysts expectations of $17856.07 million. The company’s revenue was down -2.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.27 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Johnson & Johnson was Upgraded by Goldman to ” Neutral” on Mar 14, 2016. Company shares were Upgraded by Barclays on Dec 1, 2015 to ” Overweight”, Firm has raised the Price Target to $ 115 from a previous price target of $101 .
Johnson & Johnson closed down -0.6 points or -0.55% at $108.59 with 1,06,68,885 shares getting traded on Monday. Post opening the session at $108.82, the shares hit an intraday low of $108.26 and an intraday high of $109.1 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.